Dublin, Aug. 28, 2020 (GLOBE NEWSWIRE) -- The "Coronavirus Disease 2019 (COVID-19) Impact on Immunology Trials - July 2020" report has been added to ResearchAndMarkets.com's offering.
Since the beginning of March 2020, clinical trial operations were most disrupted as a result of the COVID-19 pandemic. This report summarizes the impact on immunology patient, clinical trial logistics, and key opinion leader (KOL) insights on the long-term impact of the pandemic.
Report Scope
- Global overview of changes to clinical practice and clinical trial logistics in H1 2020 in 8MM (US, EU5, Japan, Canada)
- Summary of primary research with Immunology Key Opinion Leaders
- Forward-looking perspective of potential long-term ramifications of COVID pandemic
Reasons to Buy
- Understand the impact of COVID-19 on immunology clinical trials
- Obtain a snapshot of the regulatory guidance issued by the US FDA, EMA, and Health Canada
- Understand the impact of COVID on continuity of care for immunology patients
- Understand the impact of COVID on clinical trial logistics (including trial recruitment, trial conduct, and supply chain)
- Understand the potential long-term impact of COVID on clinical trial conduct and clinical practice
Key Topics Covered
1 Immunology Trials Disrupted
1.1 Overview of Immunology Trials Disrupted
1.2 Regulatory Guidance Across the 8MM
2 KOL Insights: Continuity of Care
3 KOL Insights: Trial Logistics
3.1 Recruitment
3.2 Conduct in Isolation
3.3 Supply Chain
4 KOL Insights: Trials Looking Forward
4.1 Clinical Trials Disrupted Due to COVID
4.2 Immunology Clinical Trials Resumed
5 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/5kx76f
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.